Four independent studies show rovalpituzumab tesirine ineffective against small cell lung cancer

Ad Details

  • Ad ID: 5989

  • Added: September 7, 2021

  • Views: 6

Description

Four independent studies demonstrate that rovalpituzumab tesirine for small-cell lung cancer (SCLC) is not effective against SCLC, casting a pall over the future of the therapy and closing a door that seemed opened four years ago when the first study on the therapy was published.

Comments

0 0 votes
Article Rating
Subscribe
Notify of
guest
0 Comments
Inline Feedbacks
View all comments